Positive Findings, Collaborations, and NDA Filings

New Post Public Reply Private Reply Replies (0) Message Board
Depcom
Positive Findings, Collaborations, and NDA Filings Strengthen Pipelines - Research Report on Clovis Oncology, MannKind, TESAR...

NEW YORK, June 6, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Clovis Oncology Inc. (NASDAQ: CLVS), MannKind Corporation (NASDAQ: MNKD), TESARO Inc. (NASDAQ: TSRO), Peregrine Pharmaceuticals (NASDAQ: PPHM), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Clovis Oncology Inc. Research Report

On June 3, 2013, Clovis Oncology Inc. (Clovis Oncology) announced initial findings from the Phase I portion of its ongoing Phase I/II clinical study of CO-1686, the novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. According to the Company, three of four evaluable T790M patients treated at 900mg BID (twice-daily) achieved partial responses. Further, it reported that CO-1686 appeared well-tolerated, with no evidence of wild-type EGFR inhibition. Dr. Lecia V. Sequist of the Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, Boston, said, "It has been exciting and quite hopeful to observe that patients are responding to CO-1686 and that the side effect profile has been so mild. A drug that works effectively for EGFR acquired resistance would be welcomed by the lung cancer community." The Full Research Report on Clovis Oncology Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/6b27_CLVS]

--

MannKind Corporation Research Report

On May 31, 2013, MannKind Corporation (MannKind) announced that all follow-up visits have been completed for patients enrolled in Study 171, a Phase 3 clinical study of AFREZZA (insulin human [rDNA origin]) inhalation powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using the Company's next-generation inhaler. Study 171 is an open-label study in patients with type 1 diabetes. After a run-in period, during which all patients were optimized on their basal insulin regimen, 518 subjects were randomized to one of three arms for mealtime insulin: a control arm, in which patients utilize rapid-acting insulin, or one of two AFREZZA arms, one for the MedTone inhaler and the other for the next-generation inhaler. After the mealtime insulin was titrated, there was a 12-week observation period on stable doses of the mealtime insulin to assess HbA1c levels, which is the primary outcome parameter. The Company expects to release data from this study in the summer of 2013. The Full Research Report on MannKind Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0b44_MNKD]

--

TESARO Inc. Research Report

On June 3, 2013, TESARO, Inc. (TESARO), Breast International Group (BIG), a non-profit organization for academic breast cancer research groups from around the world, and the European Organization for Research and Treatment of Cancer (EORTC), an international, independent, multidisciplinary non-profit research organization, announced a partnership for the Phase 3 clinical development of niraparib, an orally active, potent poly (ADP-ribose) polymerase (PARP) inhibitor. TESARO, BIG and EORTC will use BIG's and EORTC's scientific and clinical expertise and network of collaborative groups and their associated hospitals and oncology research centers to accelerate the completion of the Phase 3 clinical trial of niraparib in patients with breast cancer. The primary endpoint of this trial is progression free survival (PFS), with overall survival (OS) as a secondary endpoint. TESARO expects to open this study to patients during the second half of 2013. The Full Research Report on TESARO Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/4f59_TSRO]

--

Peregrine Pharmaceuticals Research Report

On June 3, 2013, Peregrine Pharmaceuticals, Inc. (Peregrine Pharmaceuticals) reported that data was presented at the 2013 ASCO (American Society of Clinical Oncology) Meeting from two clinical trials evaluating the Company's lead clinical candidate bavituximab, a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Interim data from a Phase I trial, evaluating bavituximab plus paclitaxel therapy in patients with HER2-negative metastatic breast cancer (MBC), showed that 85% of patients were able to achieve objective tumor response, with 15% of patients achieving a complete response (CR) in accordance to Response Evaluation Criteria in Solid Tumors (RECIST). Further, the Company reported that in the second study, results from a randomized Phase II trial of bavituximab plus gemcitabine in patients with non-resectable Stage IV pancreatic cancer demonstrated more than a doubling of the overall response rate (ORR) and an improvement in overall survival (OS), including a delayed separation in the Kaplan-Maeier survival curve that is commonly seen in promising cancer immunotherapies. The Full Research Report on Peregrine Pharmaceuticals - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/df4a_PPHM]

--

Vanda Pharmaceuticals Inc. Research Report

On May 31, 2013, Vanda Pharmaceuticals Inc. (Vanda Pharmaceuticals) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tasimelteon, a circadian regulator in development for the treatment of non-24 hour disorder (Non-24) in the totally blind. Non-24 is a serious and rare, circadian rhythm disorder that affects the majority of totally blind individuals who lack light perception and, therefore, cannot synchronize their master body clock to the 24-hour day. There are currently no FDA approved products for the treatment of Non-24. The Full Research Report on Vanda Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/b7a8_VNDA]

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
For any urgent concerns or inquires, please contact us at compliance@EquityNewsNetwork.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

DriveCentric and Dealer Pay Join Forces for Enhanced CRM Payments

Updated Category News Views 271

DriveCentric Partners with Dealer Pay for Seamless Payment Integration DriveCentric is making waves in the automotive industry with its recent partnership with Dealer Pay. This collaboration aims to revolutionize how dealerships handle customer payments within their CRM systems. By integrating Dealer Pay's payment solutions into DriveCentric's platform, dealerships can...

Continue Reading
Investigation into Coty Inc. Reveals Potential Issues Ahead

Updated Category News Views 455

Concerns Surrounding Coty Inc. Pomerantz Law Firm is currently looking into claims related to Coty Inc. (NYSE: COTY), a significant player in the beauty industry. Investors who have stakes in Coty are encouraged to understand the implications of these developments and how they might affect their investments. Danielle Peyton at the Pomerantz Firm is available for inquiries...

Continue Reading
Harnessing AI for Executive Decision-Making Excellence

Updated Category News Views 67

Transformative AI Tools for Leaders In today's fast-paced business world, leveraging advanced technology can greatly influence decision-making. Rossman Partners has launched a robust AI-driven advisory tool called Big Bet Leadership GPT. This cutting-edge solution is tailored to assist executives and entrepreneurs in navigating high-pressure scenarios, boosting their...

Continue Reading
Tesla's Meteoric Rise: Exploring the Impact of China

Updated Category News Views 240

Tesla's Remarkable Stock Performance Tesla Inc. (NASDAQ: TSLA) has proven time and again to be a formidable player, not only in the electric vehicle (EV) sector but also in the stock market. The company's stock has shown impressive gains, rising approximately 55.82% within a brief period. Over the past year, TSLA has seen significant growth of 45.02%, and year-to-date, it...

Continue Reading
Metagenomi Faces Legal Challenges Amid Partnership Fallout

Updated Category News Views 133

Metagenomi's Class Action Lawsuit Overview Investors of Metagenomi Inc. (NASDAQ: MGX) need to be aware of a class action lawsuit that has been initiated, seeking accountability after critical revelations about the company's operations. This legal action revolves around securities purchased in the defined class period, putting pressure on the company's management to...

Continue Reading